Conversely, better outcomes have been observed for patients showing particularly strong immune response features, such as highly CD8+ lymphocytes infiltrated tumors and MCCs showing no primary (MCC of unknown primary), which have higher tumor mutational burden and drive strong immune response [87, 88]. This evidence concerns the gene CD8A and neoplasm.